Trevi Health Ventures

Trevi Health Ventures

Trevi Health Ventures operates from New York as a private equity firm focused exclusively on the healthcare sector. The firm pursues a multi-stage strategy spanning venture capital, growth equity, and buyout transactions. Its investment scope covers early-stage seed and start-up opportunities, expansion-stage and late-stage financings, and control-oriented recapitalizations. This structure positions Trevi to partner with companies across their full lifecycle, from initial clinical validation through commercial scale-up. The firm targets the healthcare industry broadly, evaluating opportunities in digital health, healthcare services, and biopharmaceuticals. Its venture-stage activity includes seed and start-up commitments to emerging therapeutics platforms and healthtech companies. The growth and late-stage practice supports established healthcare businesses pursuing geographic expansion, accretive acquisitions, or operational transformation ahead of a liquidity event. On the buyout side, Trevi executes recapitalizations of healthcare-services companies with durable reimbursement profiles and demonstrated unit-level economics. The firm invests across the United States, with additional capacity to evaluate opportunities in major European markets. Confirmed portfolio positions remain undisclosed in public record. Trevi operates as a lean, deal-driven organization structured for investment pace rather than AUM accumulation. The firm has not publicly disclosed its total deployment capital or number of investment professionals. No additional offices beyond New York have been identified. Trevi's operational footprint appears concentrated — a single-location structure consistent with generalist healthcare private equity firms that run concentrated portfolios and favor deep diligence over origination volume. Adjacent vehicles, philanthropic affiliates, and co-investor club memberships are not publicly documented. The firm's structural differentiator rests in its multi-stage mandate within a single-sector focus. Most healthcare investors commit to either venture-stage science risk or cash-flowing buyout assets; Trevi bridges both, potentially allowing capital to compound within the same sector knowledge base as portfolio companies mature. This architecture places a significant burden on the investment team — requiring fluency in pre-revenue biotech diligence, growth-stage healthcare underwriting, and control-oriented private equity execution simultaneously. Succession and governance arrangements are not publicly disclosed.